ATE435302T1 - Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken - Google Patents
Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkrankenInfo
- Publication number
- ATE435302T1 ATE435302T1 AT03747881T AT03747881T ATE435302T1 AT E435302 T1 ATE435302 T1 AT E435302T1 AT 03747881 T AT03747881 T AT 03747881T AT 03747881 T AT03747881 T AT 03747881T AT E435302 T1 ATE435302 T1 AT E435302T1
- Authority
- AT
- Austria
- Prior art keywords
- rivastigmine
- determination
- treatment success
- apoe genotype
- predicting treatment
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101150037123 APOE gene Proteins 0.000 title 1
- 102100029470 Apolipoprotein E Human genes 0.000 title 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 title 1
- 229960004136 rivastigmine Drugs 0.000 title 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 abstract 1
- 108010025628 Apolipoproteins E Proteins 0.000 abstract 1
- 102000013918 Apolipoproteins E Human genes 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000003205 genotyping method Methods 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40169402P | 2002-08-07 | 2002-08-07 | |
| PCT/EP2003/008719 WO2004015140A1 (en) | 2002-08-07 | 2003-08-06 | Methods for the treatment of dementia based on apo e genotype |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE435302T1 true ATE435302T1 (de) | 2009-07-15 |
Family
ID=31715721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03747881T ATE435302T1 (de) | 2002-08-07 | 2003-08-06 | Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20060160079A1 (de) |
| EP (1) | EP1529116B1 (de) |
| JP (1) | JP2005534710A (de) |
| CN (1) | CN1681941A (de) |
| AT (1) | ATE435302T1 (de) |
| AU (1) | AU2003266967B2 (de) |
| BR (1) | BR0313588A (de) |
| CA (1) | CA2494585A1 (de) |
| DE (1) | DE60328198D1 (de) |
| DK (1) | DK1529116T3 (de) |
| ES (1) | ES2327914T3 (de) |
| IL (1) | IL166466A0 (de) |
| PT (1) | PT1529116E (de) |
| WO (1) | WO2004015140A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| WO2006014755A2 (en) * | 2004-07-20 | 2006-02-09 | Wyeth | Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer’s disease |
| US20060228728A1 (en) * | 2005-01-31 | 2006-10-12 | Perlegen Sciences, Inc. | Genetic basis of Alzheimer's disease and diagnosis and treatment thereof |
| US7740593B2 (en) | 2005-12-09 | 2010-06-22 | Senorx, Inc | Guide block for biopsy or surgical devices |
| EP2179284B1 (de) | 2007-07-31 | 2016-09-28 | Accera, Inc. | Verwendung genomischer und ketogener verbindungen zur behandlung von beeinträchtigten kognitiven funktionen |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9125881B2 (en) | 2008-07-03 | 2015-09-08 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
| WO2015020523A1 (en) | 2013-08-07 | 2015-02-12 | Stichting Vu-Vumc | Biomarkers for early diagnosis of alzheimer's disease |
| AU2018239433B2 (en) | 2017-03-21 | 2024-02-01 | Indiana University Research And Technology Corporation | A genetically modified mouse expressing human APOE4p and mouse Trem2 p.R47H and methods of use thereof |
| RS61704B1 (sr) * | 2017-05-24 | 2021-05-31 | H Lundbeck As | Kombinacija antagonista 5-ht6 receptora i inhibitora acetilholinesteraze za upotrebu u lečenju alchajmerove bolesti kod subpopulacije pacijenata koji nose apoe4 alele |
| EP3809838B1 (de) * | 2018-06-21 | 2026-04-01 | The Jackson Laboratory | Genetisch modifizierte mausmodelle der alzheimer-krankheit |
| WO2020176846A2 (en) * | 2019-02-28 | 2020-09-03 | The Rockefeller University | Apoe genotyping in cancer prognostics and treatment |
| JP7689964B2 (ja) | 2019-12-13 | 2025-06-09 | インスピルナ,インコーポレーテッド | 金属塩及びその使用 |
| CN117886933A (zh) * | 2023-12-28 | 2024-04-16 | 上海良润生物医药科技有限公司 | 一种载脂蛋白e检测试剂及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2142300C (en) * | 1992-10-13 | 2005-08-23 | Allen D. Roses | Methods for detecting alzheimer's disease |
| CA2111503A1 (en) * | 1993-12-15 | 1995-06-16 | Mcgill University | Apolipoprotein e polymorphism and alzheimer's disease |
| FR2765591B1 (fr) * | 1997-07-01 | 2002-08-09 | Pasteur Institut | Procede de diagnostic de la maladie d'alzheimer |
| CO4980891A1 (es) * | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
| JP2000069963A (ja) * | 1998-08-31 | 2000-03-07 | Igaku Seibutsugaku Kenkyusho:Kk | アポリポプロテインe4特異モノクローナル抗体 |
| IL141762A0 (en) * | 1998-10-01 | 2002-03-10 | Novartis Ag | New oral formulations |
| CA2410680A1 (en) * | 2000-06-30 | 2002-01-10 | Elan Pharmaceuticals, Inc. | Compounds to treat alzheimer's disease |
-
2003
- 2003-08-06 DK DK03747881T patent/DK1529116T3/da active
- 2003-08-06 AT AT03747881T patent/ATE435302T1/de not_active IP Right Cessation
- 2003-08-06 WO PCT/EP2003/008719 patent/WO2004015140A1/en not_active Ceased
- 2003-08-06 JP JP2004526899A patent/JP2005534710A/ja active Pending
- 2003-08-06 EP EP03747881A patent/EP1529116B1/de not_active Expired - Lifetime
- 2003-08-06 AU AU2003266967A patent/AU2003266967B2/en not_active Ceased
- 2003-08-06 US US10/523,047 patent/US20060160079A1/en not_active Abandoned
- 2003-08-06 CN CNA038212528A patent/CN1681941A/zh active Pending
- 2003-08-06 DE DE60328198T patent/DE60328198D1/de not_active Expired - Lifetime
- 2003-08-06 BR BR0313588-8A patent/BR0313588A/pt not_active Application Discontinuation
- 2003-08-06 CA CA002494585A patent/CA2494585A1/en not_active Abandoned
- 2003-08-06 PT PT03747881T patent/PT1529116E/pt unknown
- 2003-08-06 ES ES03747881T patent/ES2327914T3/es not_active Expired - Lifetime
-
2005
- 2005-01-24 IL IL16646605A patent/IL166466A0/xx unknown
-
2007
- 2007-11-16 US US11/941,420 patent/US20080214662A1/en not_active Abandoned
-
2010
- 2010-06-03 US US12/793,436 patent/US20100240744A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005534710A (ja) | 2005-11-17 |
| AU2003266967B2 (en) | 2006-11-16 |
| AU2003266967A1 (en) | 2004-02-25 |
| US20060160079A1 (en) | 2006-07-20 |
| EP1529116A1 (de) | 2005-05-11 |
| WO2004015140A1 (en) | 2004-02-19 |
| ES2327914T3 (es) | 2009-11-05 |
| DE60328198D1 (de) | 2009-08-13 |
| US20080214662A1 (en) | 2008-09-04 |
| DK1529116T3 (da) | 2009-11-09 |
| CN1681941A (zh) | 2005-10-12 |
| IL166466A0 (en) | 2006-01-15 |
| PT1529116E (pt) | 2009-09-10 |
| EP1529116B1 (de) | 2009-07-01 |
| CA2494585A1 (en) | 2004-02-19 |
| US20100240744A1 (en) | 2010-09-23 |
| BR0313588A (pt) | 2005-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60328198D1 (de) | Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken | |
| EP1788938A4 (de) | System, software und verfahren zur detektion von schlafgestörter atmung mithilfe eines elektrokardiogramms | |
| ATE488251T1 (de) | Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen | |
| EP1463531A4 (de) | Verfahren zur hemmung okularer vorgänge | |
| MX2009013649A (es) | Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma. | |
| DE60326748D1 (de) | Verfahren zur identifizierung des brustkrebsrisikos | |
| ATE519503T1 (de) | Verfahren zur behandlung von patienten mit hepatitis c | |
| WO2004101806A3 (en) | Allele-specific expression patterns | |
| ATE503563T1 (de) | Blockverhältnisverbesserendes mittel für permeable membran, verfahren zur blockverhältnisverbesserung, permebale membran und wasserbehandlungsverfahren | |
| ATE397098T1 (de) | Verfahren zur diagnostik von eierstock endometriose | |
| ATE415488T1 (de) | Träger zum nachweis von genen und seine verwendung zur feststellung der wirksamkeit einer interferontherapie | |
| WO2004043232A3 (en) | Methods for identifying risk of melanoma and treatments thereof | |
| WO2005014846A3 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| DE602006012456D1 (de) | Kühlgerät, steuerverfahren für das kühlgerät und verfahren zur bestimmung von anomalien | |
| DE602005023363D1 (de) | Vorrichtung und Verfahren zur Authentifizierung von Blutgefässen | |
| WO2006022619A3 (en) | Methods for identifying risk of type ii diabetes and treatments thereof | |
| WO2006028999A3 (en) | Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy | |
| DE602005020113D1 (de) | Verfahren zur behandlung von akuten rhinosinusitis | |
| ATE487947T1 (de) | Verfahren zur diagnose und behandlung auf nr2- peptiden beruhender zerebrovaskulärer ereignisse | |
| WO2007013360A3 (en) | Pancreatic cancer related gene cst6 and gabrp | |
| ATE543429T1 (de) | Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür | |
| WO2002053018A3 (en) | Method of detecting polymorphisms associated with breast carcinoma in mhc genes | |
| DE602004002692D1 (de) | Verfahren zur Herstellung von Topiramate | |
| DE602005016697D1 (de) | Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen | |
| WO2005118834A3 (en) | Methods for identifying risk of breast cancer and treatment thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1529116 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |